Cullinan Oncology LLC (CGEM)
Healthcare
Biotechnology
16.50 $
-5.8%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Cullinan Oncology LLC (CGEM)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 72.0% of the shares are freely tradable; institutional investors hold 107.8%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
107.8%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
0.4%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
72.0%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
18.9%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
62Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Lynx1 Capital Management, LP | 14.58 | 8,963,500 | +0.0 | 03/31/2026 |
| MPM Oncology Impact Management LP | 12.44 | 7,648,268 | +0.0 | 03/31/2026 |
| Bvf Inc | 9.36 | 5,750,683 | +0.0 | 03/31/2026 |
| BlackRock Inc | 7.24 | 4,449,966 | +1.1 | 03/31/2026 |
| Vanguard Group Inc | 5.37 | 3,298,504 | +12.1 | 12/31/2025 |
| Kynam Capital Management, LP | 5.07 | 3,114,132 | +0.0 | 03/31/2026 |
| State Street Corp | 4.14 | 2,544,115 | +15.8 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.04 | 2,483,034 | +0.0 | 03/31/2026 |
| T. Rowe Price Associates, Inc. | 3.30 | 2,029,719 | +4,201.4 | 03/31/2026 |
| Blue Owl Capital Holdings LP | 3.11 | 1,909,764 | -18.8 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.